A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Amgen0 sites2,423 target enrollmentSeptember 2002

ConditionsAnemia

DrugsAranesp

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Anemia
Sponsor: Amgen
Enrollment: 2423
Primary Endpoint: Patient reported outcomes
Status: Completed
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy supported with Aranesp®.

Registry

clinicaltrials.gov

Start Date

September 2002

End Date

December 2003

Last Updated

17 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Amgen

Eligibility Criteria

Inclusion Criteria

•Subjects with nonmyeloid malignancy(ies)
•Anemia (hgb less than or equal to 11.0 g/dL) due to cancer and chemotherapy

Exclusion Criteria

•Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS)
•Unstable cardiac disease or anemia due to other causes